Main Menu
Search
Close this search box.
Donate
Sign Up
POWERED BY OPEN COLLABORATIVE RESEARCH

The End ME/CFS & Long COVID Project: Advancing the Latest Research in Chronic Complex Diseases

The End ME/CFS and Long COVID Project encompasses the latest OMF-supported and facilitated research conducted within six ME/CFS Collaborative Research Centers (CRCs). OMF’s guiding strategy focuses on open, collaborative research so that precise diagnostic tools and life-changing treatments can be available to people with related chronic complex diseases as soon as possible.

Funding an internationally-based research network instead of single researchers ensures the stability and collaboration essential for an outcomes-focused, transparent, and multi-pronged approach to finding answers

OMF COLLABORATIVE NETWORK

The six CRCs are working collaboratively to build a repository of data about ME/CFS and  Long COVID. This data is essential to develop diagnostic technologies, understand the molecular basis of the diseases,  and uncover effective diagnostic tools and treatments.

ME / CFS Collaborative
Research Center

at Stanford University
See the research

The Ronald G. Tompkins Harvard ME/CFS Collaboration

at Harvard Affiliated Hospitals
See the research

ME / CFS Collaborative
Research Center

at Uppsala, Sweden
See the research

ME / CFS Collaborative
Research Center

at the CHU Sainte-Justine/
Université de Montréal​​
See the research

Melbourne
ME / CFS Collaboration

at Melbourne, Australia
See the research

Computational Research Center for Complex Diseases

Harvard Medical School and Stanford Genome Technology Center
See the research

Major OMF Supported Research Initiatives

With oversight from OMF’s Boards of Directors and Scientific Advisory Board, the following research projects further OMF’s Strategic Goals to improve the diagnosis and treatment of ME/CFS and Long COVID.

Current Research

Publications of OMF Funded Research

  1. Huang, K., et al. (2024). Discriminating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and comorbid conditions using metabolomics in UK Biobank. Commun Med, 4(248). doi:10.1038/s43856-024-00669-7 (Melbourne ME/CFS Collaboration)
    • Read a summary of the paper here.
  2. Abujrais, S., Vallianatou, T., and Bergquist, J. (2024). Untargeted Metabolomics and Quantitative Analysis of Tryptophan Metabolites in Myalgic Encephalomyelitis Patients and Healthy Volunteers: A Comparative Study Using High-Resolution Mass Spectrometry. ACS Chem. Neurosci. doi:10.1021/acschemneuro.4c00444 (Collaborative Center at Uppsala)
    • Read a summary of the paper here.
  3. Jahanbani, F., et al. (2024). Longitudinal cytokine and multi-modal health data of an extremely severe ME/CFS patient with HSD reveals insights into immunopathology, and disease severity. Front. Immunol, 15. doi:10.3389/fimmu.2024.1369295 (Collaborative Center at Stanford)
    • Read a summary of the paper here.
  4. Annesley, D., et al. (2024). Unravelling shared mechanisms: insights from recent ME/CFS research to illuminate long COVID pathologies. Trends Mol Med., 30(5), 443-458. doi:10.1016/j.molmed.2024.02.003 (Melbourne ME/CFS Collaboration)
    • Read a summary of the paper here..
  5. Abujrais, S., Ubhayasekera, S.J.K.A., and Bergquist, J. (2024). Analysis of tryptophan metabolites and related compounds in human and murine tissue: development and validation of a quantitative and semi-quantitative method using high resolution mass spectrometry. Anal. Methods, 16, 1074-1082. doi:10.1039/d3ay01959d (Collaborative Center at Uppsala)
    • Read a summary of the paper here.
  6. Armstrong, C.W., et al. (2023). In vitro B cell experiments explore the role of CD24, CD38, and energy metabolism in ME/CFS. Front. Immunol, 14. doi:10.3389/fimmu.2023.1178882 (Melbourne ME/CFS Collaboration)
    • Read a summary of the paper here.
  7. Jensen, M.A., et al. (2023). Catalytic Antibodies May Contribute to Demyelination in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. ACS Biochemistry, 63(1), 9-18. doi:10.1021/acs.biochem.3c00433 (Collaborative Center at Stanford)
    • Read a summary of the paper here.
  8. Schutzer, S.E., et al. (2023) Myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia are indistinguishable by their cerebrospinal fluid proteomes. Annals of Medicine, 55(1), 2208372. doi:10.1080/07853890.2023.2208372 (Collaborative Center at Uppsala)
  9. Slavin, M.D., et al. (2023). Myalgic Encephalomyelitis-Chronic Fatigue Syndrome Common Data Element item content analysis. PLoS ONE, 18(9), e0291364. doi:10.1371/journal.pone.0291364 (The Ronald G. Tompkins Harvard ME/CFS Collaboration)
  10. Nääs, A., et al. (2023). Temporal pathway analysis of cerebrospinal fluid proteome in herpes simplex encephalitis. Infectious Diseases, 55(10), 694-705. doi:10.1080/23744235.2023.2230281 (Collaborative Center at Uppsala)
  11. Joseph, P., et al. (2023). Exercise Pathophysiology in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Post-Acute Sequelae of SARS-CoV-2: More in Common Than Not? CHEST, 164(3), 717-726. doi:10.1016/j.chest.2023.03.049 (The Ronald G. Tompkins Harvard ME/CFS Collaboration)
  12. Nepotchatykh, E., et al. (2023). Circulating micoRNA expression signatures accurately discriminate myalgic encephalomyelitis from fibromyalgia and comorbid conditions. Scientific Reports, 13, 1896. doi:10.1038/s41598-023-28955-9 (Collaborative Center at Montreal)
  13. Huang, K., et al. (2022). Systematic Review of NMR-Based Metabolomics Practices in Human Disease Research. Metabolites, 12(10), 963. doi:10.3390/metabo12100963 (Melbourne ME/CFS Collaboration)
  14. Horwitz, E.B., et al. (2022). When a 17-Year-Old Girl Is Diagnosed with Myalgic Encephalomyelitis: A Case Study from the Swedish Health Care System—A Parent Perspective. Case Reports in Clinical Medicine, 11(8), 280-296. doi:10.4236/crcm.2022.118041 (Collaborative Center at Uppsala)
  15. Kisiel, M.A., et al. (2022). Predictors of post-COVID-19 and the impact of persistent symptoms in nonhospitalized patients 12 months after COVID-19, with a focus on work ability. Upsala Journal of Medical Sciences, 127. doi:10.48101/ujms.v127.8794 (Collaborative Center at Uppsala)
  16. Jahanbani, F., et al. (2022). Phenotypic Characteristics of Peripheral Immune Cells of Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome via Transmission Electron Microscopy: A Pilot Study. PLoS ONE, 17(8), e0272703. doi:10.1371/journal.pone.0272703 (Collaborative Center at Stanford)
  17. Joseph, P., et al. (2022). Neurovascular Dysregulation and Acute Exercise Intolerance in ME/CFS: A Randomized, Placebo-Controlled Trial of Pyridostigmine. CHEST, 162(5), 1116-1126. doi:10.1016/j.chest.2022.04.146 (The Ronald G. Tompkins Harvard ME/CFS Collaboration)
  18. Thomas, N., et al. (2022). The underlying sex differences in neuroendocrine adaptations relevant to Myalgic Encephalomyelitis Chronic Fatigue Syndrome. Frontiers in Neuroendocrinology, 66, 100995. doi:10.1016/j.yfrne.2022.100995 (Melbourne ME/CFS Collaboration)
  19. Stanculescu, D., and Bergquist, J. (2022). Perspective: Drawing on Findings From Critical Illness to Explain Myalgic Encephalomyelitis / Chronic Fatigue Syndrome. Front Med (Lausanne), 9. doi:10.3389/fmed.2022.818728 (Collaborative Center at Uppsala)
  20. Stanculescu, D., et al. (2021). Lessons From Heat Stroke for Understanding Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Frontiers in Neurology, 12. doi:10.3389/fneur.2021.789784 (Collaborative Center at Uppsala)
  21. Chang, C-J., et al. (2021). A Comprehensive Examination of Severely Ill ME/CFS Patients. Healthcare, 9(10), 1290. doi:10.3390/healthcare9101290 (Collaborative Center at Stanford)
    • Read a summary of the paper here.
  22. Stanculescu, D., Larsson, L., and Bergquist, J. (2021). Theory: Treatments for Prolonged ICU Patients May Provide New Therapeutic Avenues for ME/CFS (ME/CFS). Front Med (Lausanne), 7(8), 672370. doi:10.3389/fmed.2021.672370 (Collaborative Center at Uppsala)
    • Read a summary of the paper here.
  23. Al-Karagholi, M.A-M., et al. (2021). Phase 1 study to access safety, tolerability, pharmacokinetics09, and pharmacodynamics of kynurenine in healthy volunteers. Pharmacol Res Perspect, 9(2), e00741. doi:10.1002/prp2.741 (Collaborative Center at Uppsala)
  24. Joseph, P., et al. (2021). Insights from Invasive Cardiopulmonary Exercise Testing of Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. CHEST, 160(2), 642-651. doi:10.1016/j.chest.2021.01.082 (The Ronald G. Tompkins Harvard ME/CFS Collaboration)
    • Read a summary of the paper here.
  25. Stanculescu, D., Larsson, L., and Bergquist, J. (2021). Hypothesis: Mechanisms That Prevent Recovery in Prolonged ICU Patients Also Underlie Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Front Med, 8. doi:10.3389/fmed.2021.628029 (Collaborative Center at Uppsala)
    • Read a summary of the paper here.
  26. Sachdeva, S., Davis, R.W., and Saha, A.K. (2021). Microfluidic Point-of-Care Testing: Commercial Landscape and Future Directions. Front. Bioeng. Biotechnol., 8. doi:10.3389/fbioe.2020.602659 (Collaborative Center at Stanford).
  27. Nepotchatykh, E., et al. (2020). Profile of circulating microRNAs in myalgic encephalomyelitis and their relation to symptom severity, and disease pathophysiology. Scientific Reports, 10, 19620. doi:10.1038/s41598-020-76438-y (Collaborative Center at Montreal)
    • Read a summary of the paper here
  28. Bynke, A., et al. (2020). Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients – A validation study in plasma and cerebrospinal fluid from two Swedish cohorts. Brain, Behavior, & Immunity – Health, 7, 100107. doi:10.1016/j.bbih.2020.100107 (Collaborative Center at Uppsala)
  29. Virhammar, J., et al. (2020). Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid. Neurology, 95(10), 445-449. doi:10.1212/WNL.0000000000010250 (Collaborative Center at Uppsala)
  30. Kashi, A.A., Davis, R.W., and Phair, R.D. (2019). The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS. Diagnostics, 9(3), 82. doi:10.3390/diagnostics9030082 (Collaborative Center at Stanford)
    • Read a summary of the paper here..
  31. Esfandyarpour, R., et al. (2019). A nanoelectronics-blood-based diagnostic biomarker for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). PNAS, 116(21), 10250-10257. doi:10.1073/pnas.1901274116 (Collaborative Center at Stanford)
    • Read a summary of the paper here.
  32. Saha, A.K., et al. (2019). Red blood cell deformability is diminished in patients with Chronic Fatigue Syndrome. Clinical Hemorheology and Microcirculation, 71(1), 113-116. doi:10.3233/CH-180469 (Collaborative Center at Stanford)
    • Read a summary of the paper here..
  33. Naviaux, R.K., et al. (2016). Metabolic features of chronic fatigue syndrome. PNAS, 113(37), E5472-E5480. doi:10.1073/pnas.1607571113 (Collaborative Center at Stanford)
    • Read a summary of the paper here.

Help us accelerate this urgent research!

Donate now

Stay updated with the latest research news

Sign up for our newsletters!
Subscribe now

Other links you might be interested in:

Collaborative Center – Uppsala
Information for Doctors
Facebook Twitter Youtube Instagram Linkedin

OMF is a non-profit 501(c)(3) organization
(EIN# 26-4712664). All donations are tax-deductible to the extent allowed by law.

Open Medicine Foundation®
29302 Laro Drive,  Agoura Hills, CA 91301 USA
Phone: 650-242-8669
info@omf.ngo

Contact Us

PRIVACY  |  COOKIE   |   CONSENT   |  MEDICAL & OTHER DISCLAIMERS

Copyright © 2024 Open Medicine Foundation. All Rights Reserved.


Consent management

Consent Preferences

Data Subject Access Request (DSAR) Form 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.


How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 
Give now from your
Donor-Advised Fund
 
Donate